

Rec'd PCT/PTO 537,895  
12 OCT 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number  
WO 2004/052421 A1

(51) International Patent Classification<sup>7</sup>: A61L 31/04

(21) International Application Number:  
PCT/NL2003/000881

(22) International Filing Date:  
11 December 2003 (11.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02102732.1 11 December 2002 (11.12.2002) EP

(71) Applicant (for all designated States except US): DSM IP  
ASSETS B.V. [NL/NL]; Het Overloon 1, NL-6411 TE  
Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SNIJDER, Carina,  
Sacha [NL/NL]; Voegezenstraat 18, NL-6137 JR Sittard  
(NL). NIELABA, Leonard, Josef, Arnold [NL/NL];  
Molenweg 84, NL-6471 HE Eygelshoven (NL).

(74) Agent: BOOTSMA, J., P., C.; DSM Intellectual Property,  
P.O. Box 9, NL-6160 MA Geleen (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SURGICAL SOFT TISSUE MESH

(57) Abstract: The invention relates to a soft and flexible surgical soft tissue mesh comprising polyethylene yarns, wherein the polyethylene yarns have a tensile strength of more than 1.0 Gpa and consist of a polyethylene with a relative viscosity of more than 5 dl/g. A further aspect of the invention is a method of producing a soft and flexible surgical soft tissue mesh comprising polyethylene yarns, wherein yarns are applied that comprise filaments made by: a) spinning at least one filament from a solution of polyethylene with a relative viscosity of more than 5 dl/g in a solvent; b) cooling the filament obtained to form a gel filament c) removing at least partly the solvent from the gel filament; and d) drawing the filament in at least one drawing step before, during or after removing solvent.

WO 2004/052421 A1

SURGICAL SOFT TISSUE MESH

5

The present invention relates to a surgical mesh and, more particularly, to a soft and flexible surgical soft tissue mesh.

Using surgical mesh for the repair and restoration of living tissue is well known. For example, in US 6,042,592 a surgical mesh is described, which is used  
10 to support and/or reinforce a damaged or weakened portion of the body. US 6,042,592 further describes that a mesh must additionally be sufficiently porous to allow for growth of tissue through the graft after implantation. A healing tissue generally grows through porous openings in the implanted mesh, thereby assimilating the mesh and adding structural integrity to the tissue.

15

U.S. Pat. No. 3,054,406 discloses another example of a surgical mesh used for repair and restoration of living tissue. The surgical mesh described therein may be woven from either monofilament or multifilament polyethylene yarns. The mesh has limited pliability when formed of monofilament yarns, and may be prone to harboring of infectious matter when formed of multifilament yarns.

20

A surgical mesh has been extremely useful in the field of repairing soft tissue such as during a hernia repair operation. Groin herniorrhaphy is among the oldest and most common surgical procedures performed. Unfortunately, the average operative result is beset by a period of discomfort with resultant disability. Techniques have been developed, such as laparoscopic herniorrhaphy, with the intent to reduce  
25 morbidity and recurrence rates. Most trials, however, have noted only a moderate improvement in the pain and disability associated with the procedure. Further, the added cost of equipment, the need for general anesthesia, and the additional operating room time required for laparoscopic herniorrhaphy indicates that this procedure is less than ideal. There continues to be a need for a procedure that can effectively address all  
30 the considerations of cost, disability, and hernia recurrence for patients with an inguinal hernia.

While the placement of a prosthetic mesh in the properitoneal space is currently performed with either a laparoscopic or an open technique, it is desirable to perform the procedure through even less invasive means. One such means  
35 contemplated involves the use of needles to deliver the mesh into the peritoneal cavity. Delivery of mesh by means of a needle, however, has heretofore hardly been possible in part due to the unavailability of a mesh which is thin enough to be passed through

the cannula of a needle, yet of sufficient tenacity and flexibility to adequately serve its intended purpose.

There is therefore a need for a surgical soft tissue mesh, which can be made having a thickness that allows the mesh to be rolled or folded and thereafter  
5 inserted into the cannula of a needle for deployment in the body and which exhibits both the soft and pliable characteristics of a mesh produced from multifilament yarns and the infection resistance of a mesh produced from monofilament yarns. In order to provide a mesh with a low thickness, the yarns of which the mesh is made should have a high tenacity or strength. However yarns with a high tenacity generally have a too low  
10 flexibility for surgical meshes.

It is the aim of the invention to provide a mesh, which combines flexibility with a sufficient tenacity to obtain a thinner mesh than the known meshes.

According to the invention this is obtained by a mesh comprising polyethylene yarns having a tensile strength of more than 1.0 GPa and consisting of a  
15 polyethylene with a relative viscosity of more than 5 dl/g.

Herewith a mesh can be obtained which is both thin and flexible enough for the surgical use mentioned above.

A surgical mesh can be produced by knitting, weaving, braiding, or otherwise forming a plurality of yarns into a mesh. Preferably the mesh of the invention  
20 is knitted.

The mesh comprises polyethylene yarns having a tensile strength of more than 1.0 GPa, preferably more than 1.5, 2.0 or even more than 3.0 GPa. Tensile strength, also simple strength, is determined on multifilament yarns as specified in ASTM D885M, using a nominal gauge length of the fibre of 500 mm, a crosshead  
25 speed of 50%/min and Instron 2714 clamps, type Fibre Grip D5618C. The polyethylene yarns in the mesh according to the invention consist of a polyethylene with a relative viscosity of more than 5 dl/g, as measured on a solution of polyethylene in decalin with a concentration of 0,05% at 135°C according to ASTM D 4020. Preferably the relative viscosity of the polyethylene is more than 10 dl/g. An advantage  
30 of a mesh comprising a yarn made from polyethylene with a relative viscosity of more than 10 dl/g is the high fatigue strength of such a mesh. The polyethylene may further comprise minor amounts of the usual additives, like catalyst residues or stabilizers.

The thickness of the yarn may vary between wide ranges. A suitable thickness for the yarns in the mesh of the invention, however, is between 10 and 500  
35 denier in view of the flexibility of the mesh.

A mesh can be produced with monofilament or multifilament yarns. Surgical mesh formed of monofilament yarn provides satisfactory reinforcement ability, but is generally stiff and has limited pliability. In contrast, surgical mesh formed of multifilament yarn is soft and flexible in comparison to mesh formed of monofilament yarn. However, mesh formed of multifilament yarn may tend to harbour infectious matter such as bacteria. Particularly, the small void areas or interstitial spaces between the filaments of multifilament yarns may promote the breeding of such bacteria. To date, surgeons typically prefer the monofilament design because of its improved resistance to harbouring of infectious matter. As a result of this choice, surgeons must forego the advantages associated with multifilament yarns.

In a special embodiment of the invention the polyethylene yarns are sheath and core yarns, having a weight ratio between the sheath and the core of below 5:1. In this sheath and core yarn the core is formed by filaments that show no or only little adhesion to each other, that is most filaments can still be separated, e.g. when the yarn is cut lengthwise or the sheath is removed. The sheath of the yarn is a substantially non-porous layer, which layer may for example have been formed from outer filaments of a precursor yarn molten together as a result of heat exposure. The precursor yarn can be a continuous multifilament yarn, but also a spun yarn made from staple fibres. Preferably the precursor yarn is a multifilament yarn. The sheath being substantially non-porous is understood to mean that no or hardly any pores or void areas can be seen, e.g. with a microscope, such that bacteria or other microorganisms will not find a breeding place. The relative thickness of the sheath should be below a certain value, such that the sheath and core yarn combines the advantages of a flexible, yet high tenacity multifilament or spun yarn with that of a monofilament being less prone to harbouring of infectious matter. Such a yarn further shows less fraying and improved resistance to ravelling. Preferably, the weight ratio between the sheath and the core is below 3:1, or even below 2:1, since this enhances flexibility, especially for thicker yarns.

The flexibility of the mesh is generally higher if a thinner yarn is applied. Very thin yarn, however, may be more difficult to handle. In a preferred embodiment, the mesh is produced from a construction, like a braid or laid cord, comprising at least two sheath and core yarns of low denier. The advantage thereof is a high flexibility, and still low risk of harbouring of infectious matter in view of the larger dimensions of interstitial spaces between the sheath and core yarns compared with filaments of a multifilament yarn.

In another preferred embodiment of the present invention, a medicinal drug (e.g. an antibiotic) has been incorporated into the yarns.

The invention further relates to a method of producing a soft and flexible surgical soft tissue mesh comprising polyethylene yarns, wherein the yarns  
5 comprise filaments made by:

- a) spinning at least one filament from a solution of polyethylene with a relative viscosity of more than 5 dl/g in a first solvent;
- b) cooling the filament obtained to form a solvent-containing gel filament;
- c) removing at least partly the solvent from the gel filament; and  
10 d) drawing the filament in at least one drawing step before, during or after removing solvent, to result in a tensile strength of more than 1.0 GPa.

Such a spinning process is generally referred to as a gel spinning process. Gel spinning of polyethylene with a relative viscosity of more than 5 dl/g (ultra high molecular weight polyethylene; UHMwPE) has been described in various  
15 publications, including EP 0205960 A, EP 0213208 A1, US 4413110, WO 01/73173 A1, and Advanced Fiber Spinning Technology, Ed. T. Nakajima, Woodhead Publ. Ltd (1994), ISBN 1-855-73182-7, and references cited therein. Suitable solvents for this spinning process are known, and include for example paraffins, mineral oil, kerosene or decalin. Spinning solvent can be removed by evaporation, extraction, or by a  
20 combination of evaporation and extraction routes.

In a preferred embodiment, the solvent is substantially completely removed, that is to a level below the content that is allowable for the envisaged application. Preferably, the yarn obtained contains less than 800 ppm of solvent, more preferably less than 500, 250, or even less than 100 ppm.

25 The invention further relates to a preferred method, further comprising a step wherein the yarns are subjected to a heat treatment, optionally in the presence of a second solvent for polyethylene, in which step a modified yarn comprising a sheath and a core is formed, with a weight ratio between sheath and core of below 5:1, preferably below 3:1, or even below 2:1. In this process the yarns may be  
30 as spun untwisted filaments, or in the form of braided, twisted or intermingled bundles of filaments, or in the form of a spun yarn.

The conditions, like temperature and residence time of the process according to the preferred method of the invention are selected to be high, respectively long enough to soften the filaments and allow them to combine at least at the surface  
35 of the yarn such that a sheath is formed, which sheath is substantially non-porous.

Conditions useful for the surface combining process include a temperature or series of oven temperatures within the melting point range of the filament polymer that allows for forming a sheath and core structure during the exposure period. The temperature at which the preferred process is carried out is preferably within the range from about 5 150° C up to about 157° C for gel spun polyethylene yarns exhibiting a relaxed melting range of 138° to about 162° C. at a 20° C/minute scan rate and having a relative viscosity of more than 5 dl/g. Residence times during which the yarn is exposed to the oven temperature are within the range from about 6 seconds to about 150 seconds. In a special embodiment of the invention, part of the drawing of the filaments may be 10 done simultaneously with the forming of a sheath and core structure. In view of the increase in length of yarn, longer ovens may be needed, which would result in longer residence times than indicated above. To prevent that the yarn is exposed to too much heat, the temperature profile applied can be adjusted, e.g. by applying a lower initial temperature, for example in the range 135-150 °C. The weight ratio between sheath 15 and core can be adjusted by increasing or decreasing the oven temperature, increasing or decreasing the residence time, or by applying a pressure to the surface of the yarns. The skilled man can find favourable settings by routine experimentation.

Optionally a second solvent can be applied to the surface of the yarn, to enhance the process of making a sheath and core yarn. Such second solvent may 20 include mineral oil (e.g. heat transfer grade mineral oil with an average molecular weight of 250-700 g/mol), paraffin oil, and vegetable oil (e.g., coconut oil), or any other solvent for polyethylene, such as decalin, or toluene. Contact between the thread or yarn and the second solvent can be performed under ambient conditions (e.g., 20°-25° C.) or under elevated temperature conditions (e.g. up to about 100-150° C. or higher). 25 This second solvent, for example mineral oil, is thought to act as a plasticiser, and enhances the efficiency of the process; permitting the process for making the sheath and core yarn to be performed at lower temperatures. After forming the sheath structure, the yarn may be subjected to an additional heat treatment at lower temperatures, which treatment will result in substantially complete removal of the 30 second solvent, or at least to below concentrations allowed as maximum for the envisaged application of the yarn. Preferably, the yarn obtained contains less than 800 ppm of solvent, more preferably less than 500, 250, or even less than 100 ppm.

Optionally the first and the second solvent are the same.

The invention also relates to a method of producing a soft and 35 flexible surgical soft tissue mesh wherein the method further comprises a step of

incorporating a medical drug into the yarns.

This step of incorporating a drug can be done by adding the medical drug to the first solvent wherein the polyethylene is dissolved. Another way to incorporate a medical drug into the yarns is to add the medical drug to the second solvent, but also other routes are possible.

In order to obtain a more stable mesh structure the yarns of the mesh can be optionally subjected to a heat-setting step. This can be done by heating the mesh under constant strain at a temperature between the melting temperature of the polyethylene and a temperature that is not more than 20 degrees below the melting temperature. During this heat-treatment, also relaxation processes may occur. The desirability of this step is dependent on the structure of the mesh; and appears less effective for a knitted mesh.

The invention further relates to a method of repairing damaged soft tissue of a patient's body, comprising a step wherein a surgical mesh according to the invention is implanted in said body to reinforce said damaged tissue. In a special embodiment of the method according to the invention, the surgical mesh is implanted using a hollow needle.

CLAIMS

1. Soft and flexible surgical soft tissue mesh comprising polyethylene yarns,  
5 characterized in that the polyethylene yarns have a tensile strength of more than 1.0 GPa and consist of a polyethylene with an relative viscosity of more than 5 dl/g.
2. Mesh according to claim 1 wherein the mesh is knitted.
3. Mesh according to claim 1 or claim 2, wherein the yarns are sheath and core  
10 yarns, having a weight ratio between the sheath and the core of below 3:1.
4. Mesh according to any of claims 1-3, wherein the yarn comprises a medical drug.
5. Method of producing a soft and flexible surgical soft tissue mesh comprising  
15 polyethylene yarns, characterized in that yarns are applied that comprise filaments made by:
  - a) spinning at least one filament from a solution of polyethylene with a relative viscosity of more than 5 dl/g in a first solvent;
  - b) cooling the filament obtained to form a solvent-containing gel filament;
  - c) removing at least partly the solvent from the gel filament; and
  - 20 d) drawing the filament in at least one drawing step before, during or after removing solvent, to result in a tensile strength of more than 1.0 GPa.
6. Method according to claim 5, further comprising a step wherein the yarns are subjected to a heat treatment to form a modified yarn comprising a sheath and a core with a weight ratio between sheath and core of below 3:1.
- 25 7. Method according to claim 6, wherein the heat treatment is performed in the presence of a second solvent for polyethylene.
8. Method according to any one claims 5-7, further comprising a step of incorporating a medical drug into the yarns by adding the drug to the first or the second solvent.
- 30 9. Method according to any one of claims 5-8, further comprising a step of heating the mesh under constant strain at a temperature between the melting temperature of the polyethylene and a temperature not more than 20 degrees below the melting temperature.



# INTERNATIONAL SEARCH REPORT

I. ational Application No

PCT/NL 03/00881

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61L31/04

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61L A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 124 136 A (FRANCIS C. USHER) 10 March 1964 (1964-03-10) column 1, line 22 - line 63 column 2, line 39 - column 3, line 59 column 4, line 26 - line 60 column 5, line 6 - line 38	1-3,5-7, 9
X	EP 0 561 108 A (UNITED STATES SURGICAL CORP) 22 September 1993 (1993-09-22) page 2, line 55 - page 3, line 7 page 3, line 41 - line 53 page 4, line 19 - page 5, line 11 claims 1-4	1-3,5-7, 9

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

27 April 2004

Date of mailing of the international search report

06/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Menidjel, R

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/NL 03/00881

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 3 054 406 A (USHER FRANCIS C) 18 September 1962 (1962-09-18) cited in the application column 1, line 8 - line 30 column 1, line 46 - line 53 column 1, line 72 -column 2, line 60 column 3, line 29 - line 61 claims 1-5</p> <p>----</p>	1-3,5-7, 9
X	<p>EP 0 205 960 A (ALLIED CORP) 30 December 1986 (1986-12-30) cited in the application column 1, line 29 - line 44 column 2, line 39 -column 3, line 26 column 3, line 34 -column 4, line 5 examples 1-13</p> <p>-----</p>	1-3,5-7, 9

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/NL 03/00881

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 3124136	A	10-03-1964	NONE	
EP 0561108	A	22-09-1993	US 5318575 A CA 2083928 A1 EP 0561108 A2	07-06-1994 04-08-1993 22-09-1993
US 3054406	A	18-09-1962	NONE	
EP 0205960	A	30-12-1986	CA 1276065 C DE 3675079 D1 EP 0205960 A2 JP 7033603 B JP 61289111 A JP 11081035 A KR 8801034 B1 US 5958582 A US 5578374 A US 5741451 A	13-11-1990 29-11-1990 30-12-1986 12-04-1995 19-12-1986 26-03-1999 15-06-1988 28-09-1999 26-11-1996 21-04-1998